CurrentUnitedHealthcarePolicy N/A

VMAT2 inhibitor therapy for Huntington's disease chorea — Prior authorization and coverage criteria

Prior authorization form and clinical criteria for coverage of vesicular monoamine transporter 2 (VMAT2) inhibitors (e.g., tetrabenazine and similar agents) to treat moderate to severe Huntington's disease chorea in adult beneficiaries.

Policy Summary

PayerUnitedHealthcare

PolicyVMAT2 inhibitor therapy for Huntington's disease chorea — Prior authorization and coverage criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit a completed prior authorization form including drug name/strength/quantity/length of therapy and documentation of diagnosis, age, concurrent therapies, and psychiatric history.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

18+Min age

dual-therapyDual-therapy check

MAOI/reserpineMAOI/reserpine

depression/suicidalityPsychiatric risk

improvement requiredRenewal requirement

Coverage Criteria

Initial and continuation coverage criteria

Covered when ALL of the following are met

Primary criteria: Beneficiary has a diagnosis of moderate to severe Huntington's Disease with signs and symptoms of chorea; beneficiary is age 18 years or older; beneficiary is not receiving dual therapy with other VMAT2 inhibitors; beneficiary is not concurrently using a MAOI or reserpine; prescriber has assessed history of depression or suicidal ideation and indicates whether beneficiary is receiving treatment and/or is stable; if prescribing tetrabenazine, beneficiary has tried and failed one preferred drug in the same class (when applicable); prescriber signature and date are provided on the form.

All checklist items on the prior authorization form must be satisfied; prescriber signature is mandatory.

The policy explicitly lists concurrent use of a MAOI (monoamine oxidase inhibitor) or reserpine as a contraindication that would preclude approval unless the issue is addressed on the prior authorization form. The clinical questions require the prescriber to confirm whether the beneficiary is concurrently using a MAOI or reserpine and the form notes that concurrent MAOI or reserpine use is a coverage exclusion and a trigger for denial if not resolved.

Requests for VMAT2 inhibitor therapy will not meet the coverage criteria when the beneficiary is under age 18 or when there is no documented diagnosis of moderate to severe Huntington's disease chorea. The form requires the prescriber to confirm both the diagnosis of moderate to severe Huntington's Disease with signs and symptoms of chorea and that the beneficiary is age 18 or older; absence of either confirmation supports a denial as not medically necessary.

Policy Summary

PayerUnitedHealthcare

PolicyVMAT2 inhibitor therapy for Huntington's disease chorea — Prior authorization and coverage criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit a completed prior authorization form including drug name/strength/quantity/length of therapy and documentation of diagnosis, age, concurrent therapies, and psychiatric history.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy Criteria

Initial therapy requirements

Initial authorization requests must include the following information and confirmations

Initial request: Provide drug name and strength; provide quantity per 30 days; select requested length of therapy (initial options: up to 30, 60, 90, 120, or 180 days); confirm diagnosis of moderate to severe Huntington's Disease with signs and symptoms of chorea; confirm beneficiary is age 18 years or older; confirm beneficiary is not receiving dual VMAT2 inhibitor therapy; confirm beneficiary is not concurrently using a MAOI or reserpine; document history of depression or suicidal ideation and whether beneficiary is receiving treatment and/or is stable; if prescribing tetrabenazine, indicate trial and failure of one preferred same-class drug (when applicable).

Completed beneficiary, prescriber, drug, and clinical information fields (including prescriber NPI and requested drug details) must be provided on the form.

Provider Actions & Prior Authorization

Prior Authorization

Prior Authorization Required

Prior Authorization Submission Requirements — The prior authorization request must specify the drug name, strength, quantity per 30 days, and length of therapy (indicate whether Initial or Continuation and select duration). Ensure beneficiary and prescriber identifying information is complete on the form.

Include beneficiary name, DOB, gender, and beneficiary ID
Include prescriber NPI and requester contact phone
Specify drug name, strength, quantity per 30 days, and length of therapy (initial vs continuation)

Step Therapy

Step Therapy Requirement

Step therapy requirement for tetrabenazine: beneficiary must have tried and failed one preferred drug in the same class prior to approval.

If prescribing tetrabenazine, indicate prior trial and failure of ONE preferred agent in class

Documentation Required

Documentation Required for Continuation

Required documentation for continuation requests — attach objective documentation demonstrating improvement from baseline.

For Continuation of Therapy attach documentation showing clinical improvement from baseline (symptom reduction, functional improvement, or clinician assessment)
Document current treatment status and stability if applicable

Denial Risk

Denial Triggers

Triggers for denial — requests will be denied if any of the following are present: concurrent MAOI or reserpine use, dual therapy with other VMAT2 inhibitors, absence of required continuation documentation, or incomplete/incorrect form completion.

Concurrent MAOI or reserpine use
Dual therapy with another VMAT2 inhibitor
Missing documentation of improvement for continuation requests
Incomplete beneficiary, prescriber, drug, or clinical information on the form

Step	Requirement	Notes
1	Failure of one preferred drug in the same class is required prior to prescribing tetrabenazine	Document trial and failure of ONE preferred same-class VMAT2 inhibitor on the prior authorization form (question 7).

Background

Huntington's disease can produce disabling involuntary movements (chorea); management of chorea in adults may include vesicular monoamine transporter 2 (VMAT2) inhibitors such as tetrabenazine and similar agents. The prior authorization form captures key safety and appropriateness checks: confirmation of a clinical diagnosis of moderate to severe Huntington's disease with chorea, age ≥ 18, absence of dual VMAT2 inhibitor therapy, and absence of concurrent use of a MAOI or reserpine. The form also requires assessment of psychiatric history (history of depression or suicidal ideation and whether the beneficiary is receiving treatment/is stable) because VMAT2 inhibitors carry risks related to depression and suicidality. For tetrabenazine specifically, the prescriber must document failure of one preferred drug in the same class prior to approval, and for continuation requests the prescriber must attach documentation showing improvement from baseline.

OpenPayer

VMAT2 inhibitor therapy for Huntington's disease chorea — Prior authorization and coverage criteria

Coverage Criteria

Initial Therapy Criteria

Continuation of Therapy

Provider Actions & Prior Authorization

Step Therapy Requirements

Quantity Limits

Definitions

Background